A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer

被引:21
|
作者
de Souza Timoteo, Ana Rafaela [1 ]
Menezes Magalhaes Goncalves, Ana Elida [2 ]
Porpino Sales, Lucas Amadeus [1 ]
Albuquerque, Betina Menezes [2 ]
Santana de Souza, Jorge Estefano [3 ]
Pascoto de Moura, Patricia Cristina [2 ]
Arruda de Aquino, Marcos Alberto [2 ]
Agnez-Lima, Lucymara Fassarela [1 ]
Petta Lajus, Tirzah Braz [1 ,2 ]
机构
[1] Univ Fed Rio Grande do Norte, Dept Biol Celular & Genet, Ave Senador Salgado Filho S-N, BR-59078970 Natal, RN, Brazil
[2] CECAN, Hosp Liga Canc, Dept Pesquisa Translac, Ave Miguel Castro 1355, BR-59062000 Natal, RN, Brazil
[3] Univ Fed Rio Grande do Norte, Inst Metropole Digital, Ave Cap Mor Gouveia,3733 Lagoa Nova, BR-59063400 Natal, RN, Brazil
关键词
Hereditary breast cancer; Multigene testing; Moderate-risk genes; Oncogenetic counseling; ATR germline mutation; OVARIAN-CANCER; INHERITED MUTATIONS; BRCA2; MUTATIONS; IDENTIFICATION; PENETRANCE; PREVALENCE; 5382INSC; 185DELAG; PROTEIN; FAMILY;
D O I
10.1007/s10549-018-4938-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeKnowledge about the germline mutational spectrum among Brazilian with hereditary breast and ovarian cancer (HBOC) is limited. Only five studies have performed comprehensive BRCAsequencing, corresponding to 1041 individuals among a Brazilian population of over 207 million people. Herein we aimed to determine the clinical and molecular characteristics of Brazilian patients who underwent oncogenetic counseling and genetic testingof a panel of high-risk and moderate-risk genes from 2009 to 2017.MethodsMassively parallel sequencing was applied in 157 individuals (132 breast cancer-affected and 25 breast cancer-unaffected individuals) selected according NCCN criteria for hereditary breast cancer. Analysis of mutation segregationin family members was performedby capillary bidirectional sequencing, clinical response after treament and survival analysis was estimated byKaplan-Meier.ResultsNineteen germline variants were identified,15 pathogenic and 4 VUS (Variants of Uncertain Significance) in 27 individuals (27/157; 17% P < 0.0001) distributed among 7 genes. Sixty-eight percent of patients (13/19) harbor mutation in BRCA genes and 32% (6/19) in moderate risk genes. This is the first study reporting ATR deleterious germline mutation in association with hereditary breast cancer. Cancer-affected patients with moderate- risk mutation present a more aggressive phenotype, with bilateral cancer (25% vs. 13%, P = 0.0305), high-grade tumors (79.2% vs. 46.3%, P = 0.0001) and triple-negative (50% vs. 22.4%, P < 0.0001). However, no difference in the 5 years overall survival was observed between BRCA and moderate risk groups.ConclusionsThis work highlights the benefits of large-scale sequencing for oncogenetic counseling and extends our understanding about the genetics of hereditary breast cancer in the multi-ethnic Brazilian population.
引用
收藏
页码:637 / 646
页数:10
相关论文
共 50 条
  • [1] A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer
    Ana Rafaela de Souza Timoteo
    Ana Élida Menezes Magalhães Gonçalves
    Lucas Amadeus Porpino Sales
    Betina Menezes Albuquerque
    Jorge Estefano Santana de Souza
    Patrícia Cristina Pascoto de Moura
    Marcos Alberto Arruda de Aquino
    Lucymara Fassarela Agnez-Lima
    Tirzah Braz Petta Lajus
    [J]. Breast Cancer Research and Treatment, 2018, 172 : 637 - 646
  • [2] The identification of germline mutations in DNA repair genes in Brazilian individuals at-risk for hereditary breast cancer
    de Souza Timoteo, Ana Rafaela
    Santana de Souza, Jorge Estefano
    Lajus, Tirzah Braz Petta
    [J]. MOLECULAR CANCER RESEARCH, 2017, 15
  • [3] Screening for germline mutations in families at-risk for hereditary breast cancer in Southern Brazil
    Palmero, E. I.
    Hainaut, P.
    Camey, S. A.
    Filho, C. M.
    da Cunha, D. R.
    dos Santos, P. K.
    Cossio, S. L.
    Schuler-Faccini, L.
    Caleffi, M.
    Ashton-Prolla, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Genetic counseling and cancer risk perception in Brazilian patients at-risk for hereditary breast and ovarian cancer.
    Palmero, EI
    Caleffi, M
    Vargas, FR
    Rocha, JCC
    Giugliani, R
    Kalakun, L
    Schuler-Faccini, L
    Ashton-Prolla, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 884S - 884S
  • [5] Frequency of germline patghogenic mutation in breast cancer patients at high risk hereditary cancer.
    Shin, Hee-Chul
    Han, Wonshik
    Lee, Han-Byoel
    Moon, Hyeong-Gon
    Lee, Eunshin
    Noh, Dong Young
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] PARP inhibitors for hereditary breast cancer with germline BRCA mutation
    Im, Seock-Ah
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S423 - S423
  • [7] Breast cancer tumor sequencing coupled with germline genetic testing aids the identification of at-risk individuals for hereditary breast cancer disorders
    Pineda-Alvarez, Daniel E.
    Michalski, Scott T.
    Russell, Meaghan
    Yang, Shan
    Song, Ihn Young
    Nussbaum, Robert L.
    Esplin, Edward D.
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [8] The “portrait” of hereditary breast cancer
    Marc Lacroix
    Guy Leclercq
    [J]. Breast Cancer Research and Treatment, 2005, 89 : 297 - 304
  • [9] Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome
    Ewald, Ingrid P.
    Izetti, Patricia
    Vargas, Fernando R.
    Moreira, Miguel A. M.
    Moreira, Aline S.
    Moreira-Filho, Carlos A.
    Cunha, Danielle R.
    Hamaguchi, Sara
    Camey, Suzi A.
    Schmidt, Aishameriane
    Caleffi, Maira
    Koehler-Santos, Patricia
    Giugliani, Roberto
    Ashton-Prolla, Patricia
    [J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2011, 9
  • [10] Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome
    Ingrid P Ewald
    Patrícia Izetti
    Fernando R Vargas
    Miguel AM Moreira
    Aline S Moreira
    Carlos A Moreira-Filho
    Danielle R Cunha
    Sara Hamaguchi
    Suzi A Camey
    Aishameriane Schmidt
    Maira Caleffi
    Patrícia Koehler-Santos
    Roberto Giugliani
    Patricia Ashton-Prolla
    [J]. Hereditary Cancer in Clinical Practice, 9